AAAAAA

   
Results: 1-18 |
Results: 18
Pharmacodynamic model of topotecan-induced time course of neutropenia
Authors: Zamboni, WC D'Argenio, DZ Stewart, CF MacVittie, T Delauter, BJ Farese, AM Potter, DM Kubat, NM Tubergen, D Egorin, MJ
Citation: Wc. Zamboni et al., Pharmacodynamic model of topotecan-induced time course of neutropenia, CLIN CANC R, 7(8), 2001, pp. 2301-2308
Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts
Authors: Kirstein, MN Houghton, PJ Cheshire, PJ Richmond, LB Smith, AK Hanna, SK Stewart, CF
Citation: Mn. Kirstein et al., Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts, CLIN CANC R, 7(2), 2001, pp. 358-366
Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction
Authors: Herrington, JD Figueroa, JA Kirstein, MN Zamboni, WC Stewart, CF
Citation: Jd. Herrington et al., Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction, CANC CHEMOT, 47(1), 2001, pp. 89-93
Topotecan-filgrastim combination is an effective regimen for mobilizing peripheral blood stem cells
Authors: Yeoh, EJA Cunningham, JM Yee, GC Hunt, D Houston, JA Richardson, SL Stewart, CF Houghton, PJ Bowman, LC Gajjar, AJ
Citation: Eja. Yeoh et al., Topotecan-filgrastim combination is an effective regimen for mobilizing peripheral blood stem cells, BONE MAR TR, 28(6), 2001, pp. 563-571
Need and potential for predictive tests of hepatic metabolism of anticancer drugs
Authors: Stewart, CF Schuetz, EG
Citation: Cf. Stewart et Eg. Schuetz, Need and potential for predictive tests of hepatic metabolism of anticancer drugs, CLIN CANC R, 6(9), 2000, pp. 3391-3392
Pharmacokinetics of irinotecan and its metabolites SN-38 and ABC in children with recurrent solid tumors after protracted low-dose irinotecan
Authors: Ma, MK Zamboni, WC Radomski, KM Furman, WL Santana, VM Houghton, PJ Hanna, SK Smith, AK Stewart, CF
Citation: Mk. Ma et al., Pharmacokinetics of irinotecan and its metabolites SN-38 and ABC in children with recurrent solid tumors after protracted low-dose irinotecan, CLIN CANC R, 6(3), 2000, pp. 813-819
Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models
Authors: Middlemas, DS Stewart, CF Kirstein, MN Poquette, C Friedman, HS Houghton, PJ Brent, TP
Citation: Ds. Middlemas et al., Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models, CLIN CANC R, 6(3), 2000, pp. 998-1007
Antitumor activity of temozolomide combined with irinotecan is partly independent of O-6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models
Authors: Houghton, PJ Stewart, CF Cheshire, PJ Richmond, LB Kirstein, MN Poquette, CA Tan, M Friedman, HS Brent, TP
Citation: Pj. Houghton et al., Antitumor activity of temozolomide combined with irinotecan is partly independent of O-6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models, CLIN CANC R, 6(10), 2000, pp. 4110-4118
Clinical use of topoisomerase I inhibitors in anticancer treatment
Authors: Rodriguez-Galindo, C Radomski, K Stewart, CF Furman, W Santana, VM Houghton, PJ
Citation: C. Rodriguez-galindo et al., Clinical use of topoisomerase I inhibitors in anticancer treatment, MED PED ONC, 35(4), 2000, pp. 385-402
Activation of CPT-11 in mice: Identification and analysis of a highly effective plasma esterase
Authors: Morton, CL Wierdl, M Oliver, L Ma, MK Danks, MK Stewart, CF Eiseman, JL Potter, PM
Citation: Cl. Morton et al., Activation of CPT-11 in mice: Identification and analysis of a highly effective plasma esterase, CANCER RES, 60(15), 2000, pp. 4206-4210
Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts
Authors: Thompson, J George, EO Poquette, CA Cheshire, PJ Richmond, LB de Graaf, SSN Ma, M Stewart, CF Houghton, PJ
Citation: J. Thompson et al., Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts, CLIN CANC R, 5(11), 1999, pp. 3617-3631
Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children
Authors: Furman, WL Stewart, CF Poquette, CA Pratt, CB Santana, VM Zamboni, WC Bowman, LC Ma, MK Hoffer, FA Meyer, WH Pappo, AS Walter, AW Houghton, PJ
Citation: Wl. Furman et al., Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children, J CL ONCOL, 17(6), 1999, pp. 1815-1824
Interpatient variability in bioavailability of the intravenous formulationof topotecan given orally to children with recurrent solid tumors
Authors: Zamboni, WC Bowman, LC Tan, M Santana, VM Houghton, PJ Meyer, WH Pratt, CB Heideman, RL Gajjar, AJ Pappo, AS Stewart, CF
Citation: Wc. Zamboni et al., Interpatient variability in bioavailability of the intravenous formulationof topotecan given orally to children with recurrent solid tumors, CANC CHEMOT, 43(6), 1999, pp. 454-460
Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines
Authors: Zamboni, WC Houghton, PJ Hulstein, JL Kirstein, M Walsh, J Cheshire, PJ Hanna, SK Danks, MK Stewart, CF
Citation: Wc. Zamboni et al., Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines, CANC CHEMOT, 43(4), 1999, pp. 269-276
Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study
Authors: Kadota, RP Stewart, CF Horn, M Kuttesch, JF Burger, PC Kepner, JL Kun, LE Friedman, HS Heideman, RL
Citation: Rp. Kadota et al., Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study, J NEURO-ONC, 43(1), 1999, pp. 43-47
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts - Response
Authors: Stewart, CF Houghton, PJ
Citation: Cf. Stewart et Pj. Houghton, Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts - Response, J NAT CANC, 90(24), 1998, pp. 1910-1911
Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase
Authors: Guichard, SM Morton, CL Krull, EJ Stewart, CF Danks, MK Potter, PM
Citation: Sm. Guichard et al., Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase, CLIN CANC R, 4(12), 1998, pp. 3089-3094
Penetration of topotecan into cerebrospinal fluid after intravenous injection
Authors: Stewart, CF Gajjar, AJ Heideman, RL Houghton, PJ
Citation: Cf. Stewart et al., Penetration of topotecan into cerebrospinal fluid after intravenous injection, ONKOLOGIE, 21, 1998, pp. 22-24
Risultati: 1-18 |